Vera Therapeutics, Inc.
NASDAQ:VERA
Overview | Financials
Company Name | Vera Therapeutics, Inc. |
Symbol | VERA |
Currency | USD |
Price | 43.82 |
Market Cap | 2,402,549,814 |
Dividend Yield | 0% |
52-week-range | 9.83 - 50.78 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Marshall Fordyce M.D. |
Website | https://veratx.com |
An error occurred while fetching data.
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD